DE69824296D1 - Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol - Google Patents

Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol

Info

Publication number
DE69824296D1
DE69824296D1 DE69824296T DE69824296T DE69824296D1 DE 69824296 D1 DE69824296 D1 DE 69824296D1 DE 69824296 T DE69824296 T DE 69824296T DE 69824296 T DE69824296 T DE 69824296T DE 69824296 D1 DE69824296 D1 DE 69824296D1
Authority
DE
Germany
Prior art keywords
salmeterol
compositions
optically pure
lung diseases
treating lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69824296T
Other languages
English (en)
Other versions
DE69824296T2 (de
Inventor
P Jerussi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69824296D1 publication Critical patent/DE69824296D1/de
Publication of DE69824296T2 publication Critical patent/DE69824296T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69824296T 1997-09-16 1998-09-10 Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol Expired - Fee Related DE69824296T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US931636 1997-09-16
US08/931,636 US6254882B1 (en) 1997-09-16 1997-09-16 Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
PCT/US1998/018845 WO1999013867A1 (en) 1997-09-16 1998-09-10 Methods and compositions for treating pulmonary disorders using optically pure (s)-salmeterol

Publications (2)

Publication Number Publication Date
DE69824296D1 true DE69824296D1 (de) 2004-07-08
DE69824296T2 DE69824296T2 (de) 2005-06-30

Family

ID=25461118

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824296T Expired - Fee Related DE69824296T2 (de) 1997-09-16 1998-09-10 Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol

Country Status (19)

Country Link
US (1) US6254882B1 (de)
EP (1) EP1007008B1 (de)
JP (1) JP2001516715A (de)
KR (1) KR20010030610A (de)
CN (1) CN1270515A (de)
AT (1) ATE268166T1 (de)
AU (1) AU754275B2 (de)
BG (1) BG104240A (de)
BR (1) BR9812643A (de)
CA (1) CA2304265A1 (de)
CZ (1) CZ290394B6 (de)
DE (1) DE69824296T2 (de)
ES (1) ES2221991T3 (de)
HU (1) HUP0003488A3 (de)
IL (1) IL135022A0 (de)
NO (1) NO20001343L (de)
NZ (1) NZ503563A (de)
SK (1) SK3722000A3 (de)
WO (1) WO1999013867A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
CA2381802C (en) * 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
ES2234694T3 (es) * 1999-11-23 2005-07-01 Glaxo Group Limited Formulaciones farmaceuticas de salmeterol.
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US7378438B2 (en) * 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
CA2526222A1 (en) * 2003-05-16 2004-12-02 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease associated with matrix metalloprotease inhibitors
JPWO2004112791A1 (ja) * 2003-06-23 2006-07-27 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
EP1719507B1 (de) * 2005-04-13 2010-07-14 Astion Development A/S Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
PT95542B (pt) 1989-10-10 1999-09-30 Glaxo Group Ltd Processo para a prparacao de derivados de fenetanolamina
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026005D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
JP2001527545A (ja) * 1997-04-30 2001-12-25 ブリッジ ファーマ，インコーポレーテッド ユートマーを使用する組成物および方法

Also Published As

Publication number Publication date
ES2221991T3 (es) 2005-01-16
JP2001516715A (ja) 2001-10-02
CN1270515A (zh) 2000-10-18
AU9228398A (en) 1999-04-05
KR20010030610A (ko) 2001-04-16
WO1999013867A1 (en) 1999-03-25
ATE268166T1 (de) 2004-06-15
US6254882B1 (en) 2001-07-03
SK3722000A3 (en) 2000-07-11
EP1007008A4 (de) 2002-06-12
BG104240A (en) 2001-04-30
NO20001343D0 (no) 2000-03-15
AU754275B2 (en) 2002-11-07
HUP0003488A2 (hu) 2001-02-28
DE69824296T2 (de) 2005-06-30
CA2304265A1 (en) 1999-03-25
CZ290394B6 (cs) 2002-07-17
EP1007008B1 (de) 2004-06-02
HUP0003488A3 (en) 2003-05-28
CZ2000916A3 (cs) 2000-08-16
IL135022A0 (en) 2001-05-20
NO20001343L (no) 2000-03-15
NZ503563A (en) 2002-07-26
EP1007008A1 (de) 2000-06-14
BR9812643A (pt) 2000-08-22

Similar Documents

Publication Publication Date Title
ATE368660T1 (de) Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside
DE69824296D1 (de) Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol
DE69728730D1 (de) Verfahren zur Trennung einer Enantiomermischung
DE69118359D1 (de) Optisch reines r(-)albuterol zur behandlung von asthma
DE59300243D1 (de) Verfahren zur Herstellung von 3,5-Difluoranilin.
NO306059B1 (no) Fremgangsmåte for racematspaltning av tramadol
DE69828191D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin
DE69602880T2 (de) Verfahren zur Herstellung von 1,2-Dichlorethan
DE59407675D1 (de) Verfahren zur Herstellung von 6H-Dibenz-(c,e)(1,2)-oxaphosphorin-6-on
DE59712943D1 (de) Verfahren zur herstellung von (s)- oder (r)-3,3,3-trifluor-2-hydroxy-2-methylpropionsaüre
DE69717205D1 (de) Verfahren zur Herstellung von Wasserstoff enthaltenden fluorinierten Alkanen
DE59601601D1 (de) Verfahren zur Reindarstellung von trans- und cis-4-Hydroxy-2,2,6-trimethyl-cyclohexan-1-on aus Isomerengemischen
DE69603530T2 (de) Verfahren zur Herstellung von 1,1-Difluorethan
DE50309260D1 (de) Verfahren zur herstellung von bicalutamid
ATE411281T1 (de) Verfahren zur herstellung von s-aryl-cystein
DE59600661D1 (de) Verfahren zur Herstellung von d,I-Menthol
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
DE69410222T2 (de) Verfahren zur Herstellung von optisch aktiven Erythro-3-amino-1,2-epoxy-Verbindungen
DE69223880T2 (de) Verfahren zur Herstellung von gereinigtem 3,4-Epoxycyclohexyl-Methyl (Meth)Acrylat .
DE69802329D1 (de) Verfahren zur Herstellung von 3,4 disubstituirten Dinitroanilinen
DE69718690T2 (de) Verfahren zur Herstellung von optisch-aktivem 2-halogen-1-(substituiertes Phenyl)ethanol.
DE69500601D1 (de) Verfahren zur Herstellung von Dianthrachinon-N,N'-dihydroazin
DE69801789T2 (de) Verfahren zur Herstellung von optisch aktiven 1,2,4,-Butantriolen
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
DE69813388T2 (de) Verfahren zur Herstellung von 2,4-Oxazolidindion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee